cigna glp-1 coverage news today Your Weight-Loss Drugs Are Next on the Corporate Chopping Block Cigna is making GLP-1 coverage

Meet all 5 and you have a documented case for approval

Some individuals with favorable genetic profiles may respond modestly, while others with less optimized variants may achieve significant results through consistent medication use, lifestyle adherence, and provider support

Adverse events such as diarrhea, constipation, nausea, and vomiting associated with the GLP-1 RAs overlap with those seen with cancer treatments, so the patient who is undergoing treatment with an emetogenic regimen for cancer will likely experience additional weight loss, which can lead to nutritional deficiencies, loss of lean muscle mass, and loss of bone mass

April 30, 2026 regulatory update: On April 30, 2026, the FDA announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list for outsourcing facilities, finding no clinical need for large-scale compounding of those substances

This is a rare but serious condition

Maybe mild nausea appears